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Graphical Abstract 
Functionalized regioisomeric haptens of azoxystrobin have been prepared following a modular 
synthetic strategy, and high-affinity and stereoselective antibodies have been generated thereof. 
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Abstract 
The immune response to regioisomeric haptens of azoxystrobin with varied derivatization sites was 
studied. Based on the Sonogashira and Suzuki-Miyaura couplings and following a straightforward 
modular design, we have synthesized four haptens with the same linker anchored through C−C 
bonds and located at different sites of the molecule. The most stereoselective antibodies were 
produced from immunogens with the spacer arm at a distal position from the β-methoxyacrylate 
moiety characteristic of strobilurins. Moreover, we observed that assay cross-reactivity was reliant 
on the functionalization site of the competitor derivative. Finally, the antibody binding site was 
explored using synthetic chemical analogues.  
*Revised Manuscript ( Including Graphical Abstract )
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1. Introduction 
The generation of antibodies against small organic molecules has a broad applicability in the 
medical, environmental and analytical sciences. During the past decades, antibodies have been 
raised and immunoassays have been developed for the detection and quantification of chemical 
substances of clinical interest, such as hormones
1
 and drugs of abuse,
2
 as well as antibiotic
3
 and 
pesticide
4
 residues in environmental and food samples. 
In order to produce antibodies against a small organic molecule and for the further development 
of a sensitive immunoassay, it is necessary to covalently link the molecule (or a synthetic analogous 
hapten) to a carrier protein. This bioconjugate is capable of stimulating the immune system and 
producing antibodies against the target molecule. The usual way of coupling a hapten to a carrier 
antigen is to synthesize, first, a derivative that incorporates a spacer arm, generally consisting in a 
linear hydrocarbon chain of a certain length, most frequently between three and six carbon atoms, 
which is ended in a functional group that can be used for the subsequent conjugation to the carrier 
molecule. The design and synthesis of such functionalized derivatives of the parent compound is 
one of the most important steps in the process to produce high-affinity antibodies.
5
 Hapten design 
must be guided by the principle of maximizing steric, electronic and geometric similarity with the 
analyte. An ideal or optimum immunizing hapten should maintain the integrity of the framework 
and functional groups of the parent molecule, incorporating the linker chain at the site that induces 
the lowest possible changes in the electronic and conformational properties of the target compound. 
As originally stated by Karl Landsteiner,
6
 the position of the spacer arm that connects the hapten 
to the carrier protein is critical in determining the specificity of the generated antibody, which is 
usually maximal for those sites distal to the point of conjugation. In accordance with this so-called 
Landsteiner’s principle, antibody specificity is directed primarily to the portion of the hapten 
located furthest from or opposite to the functional group linking it to the carrier protein. To our 
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knowledge, however, very few studies have been carried out that allow an in-depth evaluation of 
the significance of the derivatization site over the affinity and specificity of the raised antibodies, 
and to what extent it is possible to modulate antibody specificity by using bioconjugates with 
different linker positions during immunization.
7
 
Based on these principles, we designed four regioisomeric haptens for azoxystrobin as a model 
molecule (Fig. 1). Azoxystrobin was the first discovered and patented antifungal of a new class of 
agrochemicals, the strobilurins,
8
 and it is currently the world’s best selling proprietary fungicide, 
with global annual sales over $1 billion in 2008.
9  
Each of the four haptens incorporated the same 
hydrocarbon spacer arm, but at different positions, which encompasses the entire azoxystrobin 
skeleton. All derivatives maintained the whole structure and characteristic groups of the target 
molecule, while the spacer arm was connected via a carbon−carbon single bond at a site where a 
carbon−hydrogen bond previously existed, thus introducing the least possible changes on the 
electronic properties of the tricyclic azoxystrobin framework. (Insert Fig. 1 here) 
O
NN
O
CN
CO2CH3
R3
R2
R1
Azoxystrobin (1): R1 = R2 = R3 = H; R4 = CH3
Hapten Aza6 (2): R1 = R2 = H; R3 = (CH2)5CO2H; R
4 = CH3
Hapten Azb6 (3): R2 = (CH2)5CO2H; R
1 = R3 = H; R4 = CH3
Hapten Azc6 (4): R1 =(CH2)5CO2H; R
2 = R3 = H; R4 = CH3
Hapten Azo6 (5): R1 = R2 = R3 = H; R4 = (CH2)5CO2H
OR4
 
Fig. 1. Structure of azoxystrobin and regioisomeric haptenic derivatives. 
This comprehensive approach, which has rarely been used before in the design of haptens for the 
production of antibodies against structurally complex non-rigid small organic molecules, allowed a 
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broad diversity of orientations in which the antigen was presented to the immune system, thereby 
increasing the chance of producing antibodies with enhanced binding properties. Moreover, the 
regioisomeric nature of the synthesized immunizing haptens ensured that the differences in the 
binding affinity and/or specificity of the derived antibodies could be only attributed to the variation 
in the linker attachment site. Antisera, representing the unbiased whole-response of the animal 
immune system, were chosen as the source of antibodies, and competitive enzyme-linked 
immunosorbent assay (cELISA) was employed to evaluate the affinity and selectivity of the 
produced antibodies. 
 
2. Results and discussion 
2.1. Hapten synthesis 
The preparation of each of the four regioisomeric haptens (AZa6, AZb6, AZc6 and AZo6) was 
undertaken via a concise, modular and convergent synthesis based on two consecutive nucleophilic 
aromatic substitutions of the chlorine atoms of a 4,6-dichloropyrimidine (ring b) with two 
conveniently functionalized phenols (rings a and c) (Scheme 1).
10
 The saturated carboxylated alkyl 
chain that constitutes the spacer arm in each hapten is introduced at the appropriate position of the 
aromatic ring subunit by means of a Sonogashira coupling reaction between the suitable aryl halide 
and tert-butyl hex-5-ynoate, followed by hydrogenation of the acetylenic triple bond. The 
incorporation of the carboxylated spacer arm as its tert-butyl ester is made on the basis of its easy 
acid hydrolysis to the corresponding carboxylic acid in presence of the base sensitive 
β-methoxyacrylate moiety. On the other hand, the incorporation of the β-methoxyacrylate moiety to 
the phenolic a-ring synthon is carried out by means of a Suzuki-Miyaura cross-coupling reaction 
between the appropriate aryl boronic acid and methyl (Z)-2-iodo-3-alkoxy-acrylate, a kind of 
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reaction that has been successfully used for the elaboration of the β-methoxyacrylate moiety in 
related systems.
11
 
(Insert Scheme 1 here) 
NN
O
CN
NN
Cl
CO2CH3
R2
Cl
a
b
c
CN
HOOH
R3 R
1
R4O
R2
R1
From Sonogashira coupling of 
the appropriate aryl halide with
From Suzuki-Miyaura coupling of 
the appropriate boronic acid with
(For AZa6) (For AZb6) (For AZc6)
O
R3
CO2CH3
R4O
(CH2)5CO2
tBu
CO2CH3
R4O
I
For AZa6: R1 = R2 = H; R3 = (CH2)5CO2
tBu; R4 = CH3
For AZb6: R1 = R3 = H; R2 = (CH2)5CO2
tBu; R4 = CH3
For AZc6: R1 =(CH2)5CO2
tBu; R2 = R3 = H; R4 = CH3
For AZo6: R1 = R2 = R3 = H; R4 = (CH2)5CO2
tBu
AZa6 (2), AZb6 (3), AZc6 (4) or AZo6 (5)
R1, R2, R3 and R4 as in Fig. 1
 
Scheme 1. Modular synthetic approach (a→ab→abc) for the preparation of azoxystrobin haptens. 
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2.1.1. Synthesis of hapten AZa6 (2) 
The synthesis of hapten AZa6 started with the preparation of the phenolic a-ring synthon (i.e. 
13) from 2,4-dibromophenol (Scheme 2). First, the phenolic hydroxyl group was protected with a 
conventional benzyl group using standard conditions. Regioselective lithium-bromide exchange by 
treatment of the obtained dibromobenzylether with BuLi al low temperature,
12
 followed by 
quenching with triisopropyl borate afforded the corresponding diisopropyl arylboronate, which was 
then hydrolyzed in situ to the arylboronic acid 8 by treatment with hydrochloric acid at room 
temperature. The Suzuki-Miyaura cross-coupling reaction between the arylboronic acid 8 and the 
iodoacrylate 9
13
 that completed the incorporation of the β-methoxyacrylate moiety, was undertaken 
using similar reaction conditions to the optimized once developed by Heo’s group for related 
couplings, i.e. Pd(PPh)4 as the palladium catalyst and K3PO4 as the base in a THF/H2O system at 85 
ºC.
14
 Under these conditions, the coupling of 8 and 9 took place very efficiently to give the 
α-aryl-β-methoxyacrylate 10 in 81% overall yield from starting dibromophenol (6). 
The incorporation of the hydrocarbon spacer arm was based on the Sonogashira cross-coupling 
reaction between the aryl bromide 10 and the terminal alkyne-ester 11, which had been obtained 
from commercially available hex-5-ynoic acid.
15
 The cross-coupling reaction was carried out 
efficiently using Pd(OAc)2 as the source of the palladium catalyst and 1,4-diazabicyclo[2.2.2]octane 
(DABCO) as the base in acetonitrile at room temperature.
16
 The next and last step that completed 
the preparation of the required arylic a-ring synthon involved the hydrogenation of the acetylenic 
compound 12, using 10% palladium-on-carbon as the catalyst. Under these conditions, both 
complete hydrogenation of the triple bond and hydrogenolysis of the benzyl protecting group took 
place to afford the desired phenol 13 in almost quantitative yield. 
With compound 13 at hand, the synthesis of the hapten AZa6 was readily completed following 
the designed modular strategy. The phenol 13 was reacted with 4,6-dichloropyrimidine (14) using 
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caesium carbonate as base in DMF at 0 ºC. Nucleophilic displacement of the chlorine atom by the 
phenoxide moiety took place smoothly under these conditions to afford the corresponding 
substituted pyrimidine in high yield. It must be mentioned that both, the low temperature and the 
use of cesium carbonate as the base was essential to achieve a good yield for this reaction. Thus, 
higher temperatures or the use of other bases habitually used in this type of transformation, such as 
other alkaline carbonates, gave less clean reactions resulting in lower yields of compound 15. In 
particular, substantial amounts of benzofurano-2(3H)-one and benzofurano-type derivatives, 
originated by intramolecular cyclization of the phenolic hydroxyl group of 13 with the 
β-methoxyacrylate moiety, were formed in the above conditions at room temperature or when 
K2CO3 or NaH were used as bases. 
The tricyclic carbon skeletal framework of the target hapten was completed via another 
nucleophilic substitution reaction of the chlorine atom of chloropyrimidine 15 with 2-cyanophenol 
(16). In this case, this chloride substitution reaction was much more difficult than the former and 
required heating of the reaction mixture at 85 ºC. Anyway, the reaction was also very efficient 
affording the tert-butyl ester of hapten AZa6 (17) in an excellent 93% yield. Finally, 
chemoselective trifluoroacetic acid-promoted hydrolysis of the tert-butyl ester moiety of 17 
afforded the hapten AZa6 (2) in 93% yield after its chromatographic purification.  
(Insert Scheme 2 here) 
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Br
OH
Br
B
OBn
Br
HO OH H3CO2C
OCH3
OBn
BrH3CO2C
OCH3
I
K3PO4, Pd(PPh3)4
dioxane-H2O, 85 ºC
93%
(Ph3P)2PdCl2-CuI 
DMF-Et3N, 70 ºC 
88 %
(CH2)3CO2
tBu  (11)
N N
Cl Cl
 87 %
CN
93 %
2. i) nBuLi, Et2O, -60 ºC
   ii) B(OiPr)3, -60 ºC
  iii) 1M HCl, rt
            91%
1. BrCH2Ph, K2CO3
        DMF, rt
          96 %
OBn
H3CO2C
OCH3
tBuO2C(CH2)3
100 %
H2 (4 atm),  Pd/C
AcOEt, rt
OH
H3CO2C
OCH3
tBuO2C(CH2)5
O
H3CO2C
OCH3
tBuO2C(CH2)5
NN
ClCs2CO3 
DMF, 0ºC
Cs2CO3 
DMF, 85ºC
O
H3CO2C
OCH3
RO2C(CH2)5
NN
O
HO
CN
6 8 10
12 13
(14)
15
(16)
(9)
TFA -CH2Cl2 (1:1), rt
93 %
17: R = tBu
  2: R = H (Hapten AZa6)
 
Scheme 2. Synthesis of hapten AZa6 (2). 
 
2.1.2. Synthesis of hapten AZb6 (3) 
Following the designed convergent synthetic route that is outlined in Scheme 1 for the 
preparation of the haptens, the synthesis of hapten AZb6 was accomplished with the previous 
preparation of the synthon corresponding to the pyrimidinyl b-ring, the 
2-alkyl-4,6-dichloropyrimidine 21 (Scheme 3). A key step in the preparation of this synthon was the 
incorporation of the hydrocarbon spacer arm at the C-2 position of the pyrimidine ring. Several 
attempts to prepare 20 starting from 4,6-dichloropyrimidine, via hydride substitution at C-2 with a 
lithium acetylide reagent,
17
 or 2-methyl-4,6-dichloropyrimidine, via alkylation reaction of the 
benzylic-type carbanion derived from abstraction of a proton from the methyl group,
18
 were 
unsuccessful. Therefore, we used the alternative route based on a Sonogashira cross-coupling 
reaction starting from the commercially available 2-aminopyrimidine 18. The 2-iodination of 18 
was performed in good yield by the method of Nair and co-workers,
19
 using tert-butyl nitrite to 
generate the corresponding pyrimidin-2-yl radical and diiodomethane as the source of iodine. 
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Subsequent Sonogashira cross-coupling reactions with the terminal alkyne 11 took place under very 
smooth conditions affording the 2-alkenyl pyrimidine derivative 20. It should be mentioned that, in 
spite of the recognized much better ability of iodine, as compared with chlorine, as leaving group in 
this type of coupling, the reaction also led to variable amounts of the coupling products formed 
through the chlorinated positions. This circumstance limits the yield obtained for 20 and can be 
attributed to the intrinsically higher reactivity of the 4/6-pyrimidine positions towards the oxidative 
addition step.
20
 Completion of the introduction of the hydrocarbon chain at the C-2 position of the 
pyrimidine nucleus was undertaken by hydrogenation of the triple bond of compound 20 under low 
hydrogen pressure and careful control of the progress of the reaction by TLC analysis to avoid 
excessive hydrogenolysis of the C−Cl bonds. The desired 2-alkyl pyrimidine 21 was thus obtained 
in about 68% yield from 2-iodopyrimidine 19.
 
 
With 21 available, further elaboration of the oxygen-bridged tricyclic framework of hapten 
AZb6 was achieved, as before, through two consecutive nucleophilic aromatic substitution 
reactions. First, the dichloropyrimidine 21 was reacted under very smooth basic conditions with 
methyl (E)-2-(2-hydroxyphenyl)-3-methoxyacrylate (22) to afford the pyrimidinyl-aryl ether 25 in 
60% yield. Although the preparation of α-aryl-β-methoxyacrylate 22 has already been described,21 it 
was more easily obtained in this case from commercial boronic acid 23, in only two steps and 85% 
overall yield, via Suzuki-Miyaura cross-coupling reaction with iodoacrylate 9 to give 24 and 
hydrogenolysis of the protective benzyl group. Completion of the tricyclic aromatic ring system was 
achieved through a second nucleophilic aromatic substitution reaction between chloropyrimidine 
derivative 25 and 2-cyanophenol (16) catalyzed by Cs2CO3 in DMF at 85 ºC. Finally, the synthesis 
of the required hapten AZb6 (3) was completed very efficiently by trifluoroacetic acid-promoted 
hydrolysis of the tert-butyl ester moiety of 26. (Insert Scheme 3 here) 
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N N
O Cl
(CH2)5CO2
tBu
OCH3
CH3O2C
OCH3
CH3O2C
OH
CN
N N
Cl Cl
NH2
N N
Cl Cl
I
74 %
CH3CN, 80ºC
N N
Cl Cl
73 %
(CH2)3CO2
tBu
N N
Cl Cl
(CH2)5CO2
tBu
B
OBn
HO OH H3CO2C
OCH3
OBn
tBuONO, CH2I2
(Ph3P)2PdCl2-CuI 
DMF-Et3N, rt
(CH2)3CO2
tBu  (11)
92 %
H2 (1 atm),  Pd/C
AcOEt, rt
H3CO2C
OCH3
I
K3PO4, Pd(PPh3)4
dioxane-H2O, 90 ºC
88 %
(9)
18 19 20 21
60 %
Cs2CO3, DMF, 0ºC
22
N N
O O
(CH2)5CO2R
OCH3
CH3O2C
CN
75 %
Cs2CO3 
DMF, 85ºC
(16)
HO
H2 (4 atm),  Pd/C
AcOEt, rt, 97%
22
25
23 24
TFA -CH2Cl2 (1:1), rt
95 %
26: R = tBu
  3: R = H (Hapten AZb6)
 
Scheme 3. Synthesis of hapten AZb6 (3). 
 
2.1.3. Synthesis of hapten AZc6 (4) 
The synthesis of hapten AZc6, which incorporated the hydrocarbon spacer arm at the 
cyanophenoxy moiety, required the previous preparation of the synthon corresponding to the arylic 
c-ring, the phenol 30 (Scheme 4). The first step for the preparation of this intermediate was the 
iodination of 2-cyanophenol (16), necessary for the further incorporation of the hydrocarbon spacer 
arm at this aromatic system via a palladium catalyzed cross-coupling process. This was achieved 
using the iodine-silver sulphate system in dichloromethane, which afforded regioselectively the 
iodo-phenol 27 in an excellent 84% yield. Several attempts to directly incorporate the hydrocarbon 
chain from the iodo-phenol 27, via a Sonogashira reaction with tert-butyl hex-5-ynoate (11), failed, 
even under the conditions described previously for related transformations.
22
 Therefore, the 
phenolic hydroxyl group of 27 was transformed into the corresponding benzyl ether by alkylation 
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with benzyl bromide in basic medium. The resulting benzyl ether 28 underwent the Sonogashira 
palladium-catalyzed cross-coupling reaction with the alkyne-ester 11, under similar conditions as 
those previously used in the preparation of hapten AZa6, to afford the aryl-alkyne 29 in almost 
quantitative yield. Further catalytic hydrogenation of the triple bond, with concomitant O-benzyl 
group hydrogenolysis, completed the preparation of the key phenol intermediate 30. 
With phenol intermediate 30 available, further elaboration of the whole framework of hapten 
AZc6 was straightforward following essentially the same strategy as that described above for the 
preparation of the other haptens. Thus, reaction of 30 with 4-phenyloxy-6-chloropyrimidine 31, in 
the same conditions described above for the preparation of regioisomeric compounds 17 and 26, 
afforded the tert-butyl ester of hapten AZc6 (32) in 91% yield after silica gel column 
chromatographic purification. The 4-aryloxy-6-chloropyrimidine 31 was prepared in an improved 
way (84% yield) by modification of a previously described procedure,
23
 involving the reaction 
between 4,6-dichloropyrimidine (14) and 2-(2-hydroxyphenyl)-3-methoxy acrylate (22) catalyzed 
by Cs2CO3 in DMF at 0 ºC. 
Finally, acid hydrolysis of the tert-butyl ester group of 32 furnishes the corresponding carboxylic 
acid, thus completing the synthesis of hapten AZc6 (4). 
(Insert Scheme 4 here) 
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Scheme 4. Synthesis of hapten AZc6 (4). 
 
2.1.4. Synthesis of hapten AZo6 (5) 
The synthesis of the hapten AZo6 began with the previous elaboration of the aryl a-ring synthon 
that introduced the hydrocarbon spacer arm at the β-alkoxyl group of the acrylate moiety (Scheme 
5). The preparation of this intermediate, the phenol 37, was accomplished following a similar 
strategy to that previously used for the preparation of the related phenolic compound 22 (See 
Scheme 3). The synthesis of 37 began with the achievement of β-alkoxyacrylate 34, which was 
undertaken in very high yield by the stereoselective reaction of tert-butyl 6-hydroxyhexanoate (33) 
with methyl propiolate in presence of a catalytic amount of tri-n-butyl phosphine.
24
 Subsequent 
acetoxy-iodination of the vinyl ether moiety of 34 with N-iodosuccinimide (NIS) and AcOH, 
followed by elimination of AcOH from the resulting mixture of diastereoisomeric iodoacetates 
using Et3N,
25
 afforded exclusively the methyl (Z)-α-iodo-β-alkoxyacrylate isomer 35 in good 
overall yield. The subsequent Suzuki-Miyaura cross-coupling reaction between the iodoacrylatye 35 
and the commercial arylboronic acid 23 proceeded smoothly to afford the corresponding 
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α-aryl-β-alkoxyacrylate 36, which was transformed under hydrogenolysis conditions into the 
required phenol 37 in 68% overall yield. It must be noted that the hydrogenolysis reaction of the 
O-benzyl group of 36 resulted more problematic that it might be expected on the basis of the results 
previously obtained for the related reaction of benzyl ether 24. In this case, the β-alkoxyacrylate 
moiety was partially hydrogenated (up to 50%) to the corresponding saturated system under the 
hydrogenation conditions previously used for 24. This side reaction could be minimized using a low 
pressure of hydrogen and limiting the reaction time to about 1h. 
The final steps to complete the synthesis of hapten AZo6 were, as designed, the same as those 
previously used for the preparation of hapten AZa6. Thus, reaction of phenol 37 with 
4,6-dichloropyrimidine (14) followed by reaction with 2-cyanophenol (16) and the final acid-
catalyzed hydrolysis of the tert-butyl ester moiety completed the synthesis of hapten AZo6 (5), with 
an overall yield of about 52% for the three steps. 
(Insert Scheme 5 here) 
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Scheme 5. Synthesis of hapten AZo6 (5). 
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2.2. Immunological response 
For rabbit immunization, the synthesized haptens were converted to NHS-active esters and 
covalently linked to bovine serum albumin (BSA) to afford bioconjugates with similar hapten-to-
protein molar ratios (15-20). After the fourth boost, all of the immunized animals gave rise to high 
titres (over 10
5
) against the homologous ovalbumin (OVA) conjugate. The obtained antisera also 
bound tightly to free azoxystrobin, showing affinity values in the low nanomolar range (Table 1). 
Interestingly, rabbits that were immunized with BSA−AZb6 (the hapten that was functionalized at 
the central pyrimidine ring) produced the antisera with the lowest affinity to azoxystrobin in 
homologous assays, whereas the antisera derived from the three other immunogens showed a very 
similar binding to the free compound (Fig. 2). The IC50 values in competitive assays using AZb6-
type sera could be lowered if heterologous conjugates were employed, but still these antisera 
provided the least sensitive assays, with IC50 values over 3 nM. The highest affinity was observed 
with AZo6-derived antisera in combination with the heterologous conjugate OVA−AZa6 (IC50=0.3 
nM), in which the derivatization site was at the aromatic ring located proximal to the 
methoxyacrylate moiety where the linker in AZo6 was located.  
(Insert Table 1 and Fig. 2 here) 
Table 1 
Antibody affinity for azoxystrobin by cELISAa 
 Coating conjugateb 
Antiserumc OVA−AZa6 OVA−AZb6 OVA−AZc6 OVA−AZo6 
AZa6  1.64 ± 0.26 1.62 ± 0.02 0.94 ± 0.19 1.39 ± 0.16 
AZb6  3.05 ± 0.29 19.04 ± 1.20 3.47 ± 0.23 3.32 ± 0.21 
AZc6  1.01 ± 0.17 0.79 ± 0.09 1.85 ± 0.05 1.68 ± 0.38 
AZo6  0.30 ± 0.04 1.40 ± 0.13 2.89 ± 0.37 0.93 ± 0.12 
a Values are the mean of three independent experiments. Immunoreagents were used at 
limiting concentrations. Amax values were between 0.7 and 1.5. Affinity values are 
expressed in nM. 
b Coating conjugate concentration was 0.1 µg/mL. 
c Results are for one antiserum from each immunogen. 
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Fig. 2. Inhibition curves for azoxystrobin in homologous competitive assays using antibodies 
derived from AZa6 (circles), AZb6 (up triangles), AZc6 (squares) and AZo6 (down triangles). 
 
Concerning selectivity, all of the generated antisera were highly specific to their target and 
none of them recognized any of the other strobilurin fungicides. In fact, this family of 
agrochemicals only share the small β-methoxyacrylate group or a modification of this toxophore 
moiety. Instead, the bulk of the molecule is particular and distinct for each compound. 
Azoxystrobin exists in two stereoisomeric forms, although the fungicide activity strongly relies on 
the E-isomer, which accounts for up to 98% of the technical commercial product. On the other 
hand, the Z-isomer is the main degradation product, and it appears primarily by photochemical 
reaction.
26
 During hapten synthesis, especial precaution was taken to preserve the E conformation of 
the toxophore in all derivatives. Antibodies are biomolecules most often displaying exquisite 
specificity to their target, being able to discriminate even between chiral molecules and geometric 
isomers.
27
 Accordingly, we thought it was worthwhile to challenge the generated antisera with the 
Z-isomer to further explore the fine specificity of their binding sites and to study the relationship 
between their stereoselectivity and the linker position in the parental hapten. The Z isomer of 
azoxystrobin was prepared as described by Clough et al.,
28
 and competitive assays with both 
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isomers were run in parallel. Table 2 lists the cross-reactivity values for this isomer that were 
achieved by cELISA with homologous and heterologous coating conjugates. A dissimilar response 
was clearly found for the different antisera. Following Landsteiner’s principle, the highest 
stereospecificity was obtained with AZc6-derived antisera, independently of the hapten conjugate 
that was employed in the assay. Interestingly, the Landsteiner’s principle was also applicable to the 
coating conjugate because, for all sorts of antisera, the cross-reactivity values could be lowered 
below 10% if OVA−AZc6 was used for coating, independently of the employed antiserum. 
Therefore, not only AZc6-type antisera but also AZc6 conjugates, in which the linker was placed at 
the aromatic ring located distal to the β-methoxyacrylate group, clearly afforded the best 
stereospecificity. On the contrary, if plates were coated with OVA−AZb6, AZa6-derived antisera 
bound similarly both stereoisomers (cross-reactivity close to 90%). 
(Insert Table 2 here) 
 
 
 
 
 
Finally, in order to further inquire into the specificity properties of the antibody binding site, the 
capacity of the produced antisera to distinguish between structurally quite similar molecules was 
investigated. With this aim, two structural analogues of azoxystrobin (compounds 40 and 41, Fig. 3) 
were prepared in our laboratory following a similar strategy to that used for the preparation of the 
synthetic haptens (see the Supplementary Material). Each of them contained just one modified 
Table 2 
Cross-reactivities for the azoxystrobin Z-isomer (%)a 
 Coating conjugateb 
Antiserumc AZa6 AZb6 AZc6 AZo6 
AZa6 16.0 ± 2.9 88.1 ± 4.2 1.7 ± 0.2 16.4 ± 1.3 
AZb6 51.9 ± 6.8 15.7 ± 0.9 7.3 ± 0.8 45.5 ± 7.7 
AZc6 8.0 ± 0.6 2.0 ± 0.1 2.4 ± 0.3 2.7 ± 0.3 
AZo6 21.8 ± 5.1 20.8 ± 3.6 3.0 ± 1.0 11.9 ± 3.1 
a Values are the mean of four independent experiments. 
b Coating conjugate concentration was 0.1 µg/mL. 
c Results are for one antiserum from each immunogen. 
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moiety located at opposite sites, either at the cianophenyl ring or at the acrylate group. These 
minimal changes in the azoxystrobin structure drastically reduced the affinity of the antisera for 
such analogues (cross-reactivity values were lower than 1%), thus confirming the high selectivity of 
the produced antibodies. However, differential binding behaviours to compounds 40 and 41 could 
be observed for the four types of antisera. As shown in Fig. 3, AZo6- and AZa6-derived antisera 
displayed a lower affinity towards analogue 41 (the compound without the nitrile group) than to 
analogue 40 (the compound without the methoxymethylene group). On the contrary, AZc6-type 
antibodies bound worst to compound 40 than to compound 41. In both cases, the affinity was lower 
towards the compound in which the modification was distal from the derivatization site of the 
corresponding immunizing hapten, demonstrating again that the specificity of the immune response 
was mainly directed towards the chemical moieties that were located opposite to the linker. 
(Insert Fig. 3 here) 
 
Fig. 3. Affinity of the different types of antisera towards two analogues of azoxystrobin. Black bars: 
compound 40; gray bars: compound 41. 
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3. Conclusion 
A concise modular approach for the synthesis of regioisomeric haptens for azoxystrobin has 
been designed. Distinct functionalized haptens with the same linker located at varying positions of 
the azoxystrobin framework were prepared. Following this approach, we could generate antibodies 
showing superior specificity and higher affinity than the previously reported polyclonal antibodies 
for this compound.
29
 It could also be concluded that the hapten in which the linker was placed at the 
central ring of azoxystrobin afforded antisera with lower affinity for the free molecule, probably 
because of a less efficient display of the chemical to the immune system. The prepared haptens 
provided expanded possibilities for tuning the assay sensitivity and specificity through the selection 
of optimum haptens for the preparation of solid surface-coating bioconjugates. Our study showed 
that the observed cross-reactivity for an antiserum can greatly depend on the coating conjugate that 
is employed. This observation is probably exclusive of polyclonal antibodies and it might be a result 
of the heterogeneity of this sort of immunoreagent. For comparison, further studies are being 
conducted to generate a collection of monoclonal antibodies using the described synthetic haptens. 
Finally, the produced antibodies and conjugates will be highly valuable reagents for the 
development of sensitive immunoassays applicable to monitoring programmes for the analysis of 
azoxystrobin in, for example, food and environmental samples. 
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4. Experimental 
4.1. Hapten Synthesis 
General experimental details and full characterisation data for all of the described compounds 
are given as supplementary data. 
4.1.1. Synthesis of hapten AZa6 (2) 
4.1.1.1. 1-(Benzyloxy)-2,4-dibromobenzene (7) 
Benzyl bromide (592 µL, 4.983 mmol) was added to a solution of 2,4-dibromobenzene (1.142 g, 
4.53 mmol) and anhydrous K2CO3 (688.7 mg, 4.982 mmol) in dry DMF (9.5 mL) under nitrogen. 
The mixture was stirred at rt for 1.30 h, poured into water and worked up as usual, using EtOAc to 
extract. Chromatography of the residue left after evaporation of the solvent, using hexane/EtOAc 
(from 9:1 to 8:2) as eluent, afforded the benzyl ether 7 (1.475 g, 96%) as a white solid. Mp 65−67 
ºC (from hexane). 
1
H NMR (300 MHz, CDCl3): =7.69 (d, J=2.2 Hz, 1 H), 7.40 (m, 5 H), 7.33 (dd, 
J=8.8, 2.2 Hz, 1 H), 6.80 (d, J=8.8 Hz, 1 H), 5.14 (s, 2 H). HRMS (EI): calcd for C13H10
79
Br2O 
339.9098, found 339.9097. 
4.1.1.2. 2-(Benzyloxy)-5-bromophenylboronic acid (8) 
A 1.43 M solution of BuLi in hexane (1.4 mL, 2 mmol) was added drop wise into a white slurry 
of benzyl ether 7 (685 mg, 2 mmol) in anhydrous Et2O (7.5 mL) at −60 ºC. The reaction solution 
soon turned into a clear yellowish solution that was stirred at the same temperature for 30 min and 
then treated with B(O
i
Pr)3 (462 µL, 2 mmol). The white slurry formed was stirred for 30 min at 
−60 ºC and them for 1 h at rt. The reaction mixture was quenched with 1M aqueous HCl solution (5 
mL), then stirred for 45 min and poured into water. Work up as usual, using EtOAc to extract, 
yielded a solid residue which was purified by chromatography with hexane/EtOAc (from 9:1 to 8:2) 
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as eluent, to yield the arylboronic acid 8 (557 mg, 91%) as a white solid. Mp 99−100 ºC (from 
hexane/MeOH). 
1
H NMR (300 MHz, CHCl3): =7.97 (d, J=2.6 Hz, 1 H), 7.51 (dd, J=8.8, 2.6 Hz, 1 
H), 7.41 (m, 5 H), 6.86 (d, J=8.8 Hz, 1 H), 6.05 (s, 2 H), 5.12 (s, 2 H). HRMS (ES): calcd for 
C13H12B
79
BrNaO3 [M
+
+Na]
+
 328.9961, found 328.9974. 
4.1.1.3. (E)-Methyl 2-(2-(benzyloxy)-5-bromophenyl)-3-methoxyacrylate (10) 
A mixture of iodoacrylate 9 (214 mg, 0.886 mmol), arylboronic acid 8 (272 mg, 0.886 mmol), 
K3PO4 (564.2 mg, 2.658 mmol) and Pd(PPh3)4 (51 mg, 0.044 mmol) in a mixture of dioxane (1.15 
mL) and water (233 µL), previously degasified by bubbling nitrogen under ultrasonic irradiation for 
a period of 10 min, was stirred under nitrogen at 85 ºC for 4.45 h. After this time, the reaction 
mixture was cooled down, poured into water and worked up using EtOAc as extraction solvent. 
Column chromatography, eluting with hexane/EtOAc (from 9:1 to 8:2) as eluent, gave methyl 
acrylate derivative 10 (312 mg, 93%) as a solid. Mp 121−122 ºC (from hexane/EtOAc). 1H NMR 
(300 MHz, CHCl3): =7.50 (s, 1 H), 7.342 (m, 5 H), 7.341 (dd, J=8.8, 2.5 Hz, 1 H), 7.32 (d, J=2.5 
Hz, 1 H), 6.81 (d, J=8.8 Hz, 1 H), 5.04 (s, 2 H), 3.81 (s, 3 H), 3.66 (s, 3 H) ppm. HRMS (ES): calcd 
for C18H17
79
BrNaO4 [M
+
+Na]
+
 399.0208, found 399.0207. 
4.1.1.4. tert-Butyl 6-(3-((E)-1-(methoxycarbonyl)-2-methoxyvinyl)-4-(benzyloxy)phenyl)hex-5-
ynoate (12) 
A solution of tert-butyl hex-5-ynoate (11, 194 mg, 1.154 mmol) in anhydrous degassed DMF 
(1.03 mL) was added to a mixture of aryl bromide 10 (152.3 mg, 0.40 mmol), CuI (12 mg, 0.063 
mmol) and (Ph3P)2PdCl2 (38 mg, 0.054 mmol) followed anhydrous Et3N (1.03 mL) under nitrogen 
atmosphere. The reaction mixture, initially yellow that turned deep-orange after a few minutes, was 
stirred in an oil bath at 70 °C for 22 h. It was then cooled down to rt, poured into water and worked 
up in the usual manner. Chromatography of the crude product with hexane/EtOAc (from 9:1 to 7:3) 
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as eluent afforded alkyne 12 (162 mg, 88%) as a solid. Mp 94−96 ºC (from hexane). 1H NMR (300 
MHz, CHCl3): =7.50 (s, 1 H), 7.34 (m, 5 H), 7.31 (dd, J=8.5, 2.0 Hz, 1 H), 7.25 (d, J=2.0 Hz, 1 
H), 6.84 (d, J=8.5 Hz, 1 H), 5.06 (s, OCH2, 2 H), 3.80 (s, 3 H), 3.64 (s, 3 H), 2.43 (t, J=7.2 Hz, 2 
H), 2.39 (t, J=7.2 Hz, 2 H), 1.86 (quint, J=7.2 Hz, 2 H), 1.45 (s, 9 H) ppm. HRMS (EI): calcd for 
C28H32O6 464.2199, found 464.2196. 
4.1.1.5. tert-Butyl 6-(3-((E)-1-(methoxycarbonyl)-2-methoxyvinyl)-4-(benzyloxy)phenyl)hexanoate 
(13) 
A mixture of alkyne 12 (90.3 mg, 0.195 mmol) and 10% Pd/C in EtOAc (2.4 mL) was stirred 
under an atmosphere of hydrogen at 4 atm overnight. The reaction mixture was filtered through a 
short silica gel column, using EtOAc as the eluent. The filtrate was concentrated to dryness to give 
pure the title compound 13 (73.5 mg, 100%) as a colourless oil. 
1
H NMR (300 MHz, CHCl3): 
=7.61 (s, 1 H), 7.02 (dd, J=8.2, 2.1 Hz, 1 H), 6.94 (d, J=2.1 Hz, 1 H), 6.88 (d, J=8.2 Hz, 1 H), 6.15 
(br s, 1 H), 3.88 (s, 3 H), 3.76 (s, 3 H), 2.53 (t, J=7.6 Hz, 2 H), 2.20 (t, J=7.6 Hz, 2 H), 1.60 (quint, 
J=7.6 Hz, 2 H), 1.59 (quint, J=7.6 Hz, 2 H,), 1.43 (s, 9 H), 1.34 (quint, J=7.6 Hz, 2 H) ppm. HRMS 
(EI): calcd for C21H30O6 378.2042, found 378.2031. 
4.1.1.6. tert-Butyl 6-(4-(6-chloropyrimidin-4-yloxy)-3-((E)-1-(methoxycarbonyl)-2-methoxyvinyl) 
phenyl)hexanoate (15) 
A mixture of phenol 13 (60.8 mg, 0.16 mmol), Cs2CO3 (104.5 mg, 0.32 mmol) and 
4,6-dichloropyrimidine (49.3 mg, 0.32 mmol) was dissolved in dry DMF (1.2 mL) at 0 ºC under 
nitrogen. The mixture was stirred at this temperature for 2½ h, poured into water and worked up as 
usual using EtOAc as the extraction solvent. Chromatographic purification, eluting with 
hexane/EtOAc (9:1), afforded the chloropyrimidine 15 (68.4 mg, 87%) as a slightly coloured oil. 
1
H 
NMR (300 MHz, CHCl3): =8.56 (s, 1 H), 7.42 (s, 1 H), 7.18 (dd, J=8.3, 2.0 Hz, 1 H), 7.11 (d, 
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J=2.0 Hz, 1 H), 7.05 (d, J=8.3 Hz, 1 H), 6.75 (s, 1 H), 3.72 (s, 3 H), 3.58 (s, 3 H), 2.63 (t, J=7.6 Hz, 
2 H), 2.21 (t, J=7.6 Hz, 2 H), 1.66 (quint, J=7.6 Hz, 2 H), 1.62 (quint, J=7.6 Hz, 2 H), 1.43 (s, 9 H), 
1.25 (quint, J=7.6 Hz, 2 H) ppm. HRMS (EI): calcd for C25H31
35
ClN2O6 490.1871, found 490.1860. 
4.1.1.7. tert-Butyl 6-(4-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)-3-((E)-1-(methoxycarbonyl)-2-
methoxyvinyl)phenyl)hexanoate (17) 
A mixture of chloropyrimidine 15 (61.8 mg, 0.126 mmol), Cs2CO3 (82 mg, 0.252 mmol) and 
2-cyanophenol (16, 60 mg, 0.504 mmol) in dry DMF (0.87 mL) was stirred at 85 ºC under nitrogen 
for 2½ h. The resulting orange suspension was cooled to rt, diluted with water and worked up as 
usual using EtOAc as the extraction solvent. Chromatographic purification, eluting with 
hexane/EtOAc (from 8:2 to 7:3), yielded the tert-butyl ester 17 (67.2 mg, 93%) as an oil. 
1
H NMR 
(300 MHz, CHCl3): =8.40 (d, J=0.8 Hz, 1 H), 7.71 (dd, J=7.7, 1.7 Hz, 1 H), 7.66 (ddd, J=7.7, 8.3, 
1.7 Hz, 1 H), 7.47 (s, 1 H), 7.36 (td, J=7.7, 1.0 Hz, 1 H), 7.29 (dd, J=8.3, 1.0 Hz, 1 H), 7.20 (dd, 
J=8.2, 2.3 Hz, 1 H), 7.13 (d, J=2.3 Hz, 1 H), 7.11 (d, J=8.2 Hz, 1 H), 6.40 (d, J=0.8 Hz, 1 H), 3.74 
(s, 3 H), 3.63 (s, 3 H), 2.64 (t, J=7.7 Hz, 2 H), 2.22 (t, J=7.4 Hz, 2 H), 1.67 (quint, J=7.7 Hz, 2 H), 
1.64 (quint, J=7.4 Hz, 2 H), 1.44 (s, 9 H), 1.40 (m, 2 H) ppm. HRMS (EI): calcd for C32H35N3O7 
573.2475, found 573.2481. 
4.1.1.8. 6-(4-(6-(2-Cyanophenoxy)pyrimidin-4-yloxy)-3-((E)-1-(methoxycarbonyl)-2-methoxyvinyl) 
phenyl)hexanoic acid (Hapten AZa6, 2) 
A solution of tert-butyl ester 17 (57.7 mg, 0.10 mmol) in dry CH2Cl2 (700 µL) was treated with 
CF3CO2H (700 µL) under nitrogen. The mixture was stirred at rt for 20 min, then diluted with 
benzene and concentrated to dryness in vacuum; the residue was purified by chromatography, using 
CHCl3/MeOH (95:5) as eluent, to give hapten AZa6 (2, 48 mg, 93 %) as a viscous oil. IR (NaCl): 
vmax=3219 (m), 2230 (m), 1709 (s), 1636 (s), 1589 (s), 1571 (s) cm
-1
. 
1
H NMR (300 MHz, CHCl3): 
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=8.41 (s, 1 H, H-2 pyrim), 7.71 (dd, J=7.8, 1.6 Hz, 1 H, H-3 CN-Ph), 7.66 (td, J=8.0, 1.6 Hz, 1 H, 
H-5 CN-Ph), 7.48 (s, 1 H, H-2’), 7.36 (br t, J=7.8 Hz, 1 H, H-4 CN-Ph), 7.30 (br d, J=8.0, Hz, 1 H, 
H-6 CN-Ph), 7.20 (dd, J=8.2, 2.1 Hz, 1 H, H-6 Ph), 7.13 (d, J=2.1 Hz, 1 H, H-2 Ph), 7.11 (d, J=8.2 
Hz, 1 H, H-5 Ph), 6.41 (s, 1 H, H-5 pyrim), 3.74 (s, 3 H, OCH3), 3.64 (s, 3 H, CO2CH3), 2.65 (t, 
J=7.5 Hz, 2 H, H2-6), 2.36 (t, J=7.5 Hz, 2 H, H2-2), 1.69 (quint, J=7.5 Hz, 4 H, H2-5 and H2-3), 1.43 
(m, 2 H, H2-4) ppm. 
13
C NMR (75 MHz, CHCl3): =171.93 (C-6 pyrim), 171.89 (COOH), 170.02 
(C-4 pyrim), 167.56 (CO2Me), 160.69 (C-2’), 157.91 (C-2 pyrim), 154.10 (C-1 CN-Ph), 148.08 
(C-4 Ph), 139.93 (C-1 Ph), 134.18 (C-5 CN-Ph), 133.56 (C-3 CN-Ph), 132.48 (C-2 Ph), 129.09 (C-6 
Ph), 126.05 (C-4 CN-Ph), 125.46 (C-3 Ph), 123.03 (C-6 CN-Ph), 121.67 (C-5 Ph), 115.19 (CN), 
107.25 (C-2 CN-Ph), 106.99 (C-1’), 92.33 (C-5 pyrim), 61.97 (OCH3), 51.61 (CO2Me), 35.02 (C-6), 
33.82 (C-2), 30.67 (C-5), 28.59 (C-4), 24.45 (C-3) ppm. MS (EI): m/z (%)=517 (M
+
, 18), 502 (35), 
486 (18), 474 (10), 467 (4), 458 (100), 398 (13), 305 (12), 229 (40), 189 (22), 119 (8), 75 (25). 
HRMS (EI): calcd for C28H27N3O7 517.1849, found 517.1857. 
 
4.1.2. Synthesis of hapten AZb6 (3) 
4.1.2.1. 4,6-Dichloro-2-iodopyrimidine (19) 
t
BuONO (431 µL, 3.625 mmol) was added to a solution of aminopyrimidine 18 (129.3 mg, 
0.788 mmol) and CH2I2 (3.27 mL) in anhydrous CH3CN (820 µL) under nitrogen. The reaction 
mixture was heated in an oil bath at 80 ºC for 3½ h, then cooled to rt and concentrated under 
reduced pressure. The residue was directly chromatographed on silica gel, eluting with hexane, to 
give the iodopyrimidine 19 (160 mg, 74%) as a white solid. Mp 97−98 ºC (from hexane). 1H NMR 
(300 MHz, CHCl3): =7.40 (s, 1 H) ppm. HRMS (EI): calcd for C4H
35
Cl2IN2 273.8561, found 
273.8557. 
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4.1.2.2. tert-Butyl 6-(4,6-dichloropyrimidin-2-yl)hex-5-ynoate (20) 
A solution of alkyne 20 (86 mg, 0.512 mmol) in anhydrous DMF (611 µL) and Et3N (611 µL) 
were added sequentially via syringe to a mixture of iodopyrimidine 19 (127.7 mg, 0.464 mmol), 
CuI (6.3 mg, 0.033 mmol) and (Ph3P)2PdCl2 (7.8 mg, 0.011 mmol) under nitrogen. The deep-orange 
mixture formed was stirred at rt for 2½ h, then poured into water and worked up using EtOAc to 
extract. Chromatographic purification, using hexane/EtOAc (from 9.5:0.5 to 8:2) as eluent, yielded 
the alkynylpyrimidine derivative 20 (106 mg, 73%) as a yellowish oil. 
1
H NMR (300 MHz, CHCl3): 
=7.31 (s, 1 H), 2.53 (t, J=7.2 Hz, 2 H), 2.38 (t, J=7.2 Hz, 2 H), 1.91 (quint, J=7.2 Hz, 2 H), 1.43 (s, 
9 H) ppm. HRMS (ES): calcd for C14H16
35
Cl2N2NaO2 [M
+
+Na]
+
 337.0487, found 337.0490. 
4.1.2.3. tert-Butyl 6-(4,6-dichloropyrimidin-2-yl)hexanoate (21) 
To a solution of alkynylpyrimidine 20 (101.6 mg, 0.31 mmol) in EtOAc (4 mL) was added 10% 
palladium on carbon (39.2 mg) and the stirred mixture was hydrogenated at rt under balloon 
pressure of hydrogen. After 18 h, the mixture was filtered through a pad of silica gel, washing with 
EtOAc. The filtrate was concentrated under reduced pressure and the residue was chromatographed 
on silica gel, using hexane/EtOAc (9:1) as eluent, to yield alkylpyrimidine 21 (93.8 mg, 92%) as a 
colourless oil. 
1
H NMR (300 MHz, CHCl3): =7.23 (s, 1 H), 2.89 (t, J=7.7 Hz, 2 H), 2.20 (t, J=7.7 
Hz, 2 H), 1.80 (quint, J=7.7 Hz, 2 H), 1.61 (quint, J=7.7 Hz, 2 H), 1.41 (s, 9 H), 1.38 (m, 2 H) ppm. 
HRMS (EI): calcd for C14H20
35
Cl2N2O2 318.0902, found 318.0909. 
4.1.2.4. Methyl (E)-2-(2-hydroxyphenyl)-3-methoxyacrylate (22) 
A mixture of iodoacrylate 9 (634 mg, 2.62 mmol), arylboronic acid 23 (896.2 mg, 3.93 mmol), 
K3PO4 (1.668 g, 7.86 mmol) and Pd(PPh3)4 (121.1 mg, 0.105 mmol) in a previously degasified 
mixture of dioxane (13 mL) and water (2.62 mL) was stirred under nitrogen at 90 ºC for 10 h. After 
this time, the reaction mixture was cooled down, diluted with ether and worked up. Column 
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chromatography, eluting first with CHCl3 to separate the excess of boronic acid and then with 
hexane/EtOAc (from 9:1 to 8:2), gave (E)-methyl 2-(2-(benzyloxy)phenyl)-3-methoxyacrylate (24, 
687 mg, 88%) as an oil, which had physical and spectroscopic properties identical with those 
described in the literature.
30
 
A mixture of 24 (690 mg, 0.065 mmol) and 10% Pd/C (120 mg) in EtOAc (6.3 mL) was stirred 
at rt under a pressure of hydrogen of 4 atm for 6h. The mixture was filtered through a short column 
of silica gel, eluting with EtOAc, to afford pure compound 22 (467 mg, 97%).) as an amorphous 
solid. The physical and spectroscopic properties of 22 were also identical to those described 
previously in the literature for this compound.
31 
4.1.2.5. tert-Butyl 6-(4-chloro-6-(2-((E)-1-(methoxycarbonyl)-2-methoxyvinyl)phenoxy)pyrimidin-2-
yl)hexanoate (25) 
A mixture of 4,6-dichloro pyrimidine 21 (117 mg, 0.366 mmol), Cs2CO3 (118.9 mg, 0.366 
mmol) and phenol 22 (38.2 mg, 0.184 mmol) was dissolved in dry DMF (1.4 mL) at 0 ºC under 
nitrogen. The mixture was stirred at this temperature for 2½ h. After an additional 1h at rt, the 
mixture was poured into water and worked up as usual using EtOAc as the extraction solvent. 
Chromatographic purification, eluting with hexane/EtOAc (from 95:5 to 8:2), afforded the 
chloropyrimidine 25 (54.1 mg, 60%) as a yellowish oil. 
1
H NMR (300 MHz, CHCl3): =7.45 (s, 1 
H), 7.39 (ddd, J=6.2, 8.0, 2.4 Hz, 1 H), 7.33 (dd, J=6.2, 2.4 Hz, 1 H), 7.29 (td, J=6.2, 1.2 Hz, 1 H), 
7.16 (dd, J=8.0, 1.2 Hz, 1 H), 6.48 (s, 1 H), 3.73 (s, 3 H), 3.59 (s, 3 H), 2.79 (t, J=7.7 Hz, 2 H), 2.19 
(t, J=7.6 Hz, 2 H), 1.76 (quint, J=7.7 Hz, 2 H), 1.59 (quint, J=7.6 Hz, 2 H), 1.43 (s, 9 H), 1.36 (m, 2 
H) ppm. HRMS (EI), calcd for C25H31
35
ClN2O6 490.1871, found 490.1881. 
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4.1.2.6. tert-Butyl 6-(4-(2-cyanophenoxy)-6-(2-((E)-1-(methoxycarbonyl)-2-methoxyvinyl)phenoxy) 
pyrimidin-2-yl)hexanoate (26) 
A mixture of chloropyrimidine 25 (67.8 mg, 0.138 mmol), Cs2CO3 (89.9 mg, 0.276 mmol) and 
2-cyanophenol (16, 65.7 mg, 0.552 mmol) in dry DMF (0.96 mL) was stirred at 85 ºC under 
nitrogen for 4 h. The reaction mixture was cooled to rt, diluted with water and worked up as usual 
using EtOAc as the extraction solvent. Chromatographic purification, eluting with hexane/EtOAc 
(from 9:1 to 7:3) as eluent, afforded the tert-butyl ester 26 (59.4 mg, 75%) as a yellowish oil. 
1
H 
NMR (300 MHz, CHCl3): =7.68 (dd, J=7.7, 1.5 Hz, 1 H), 7.63 (ddd, J=7.7, 8.2, 1.5 Hz, 1 H), 7.49 
(s, 1 H), 7.39 (ddd, J=6.8, 8.0, 2.3 Hz, 1 H), 7.33 (dd, J=6.8, 2.3 Hz, 1 H), 7.32 (td, J=7.7, 1.4 Hz, 1 
H), 7.28 (td, J=6.8, 1.2 Hz, 1 H), 7.26 (br d, J=8.2 Hz, 1 H), 7.20 (dd, J=8.0, 1.2 Hz, 1 H), 6.08 (s, 
1H), 3.75 (s, 3 H), 3.62 (s, 3 H), 2.65 (t, J=7.7 Hz, 2 H), 2.14 (t, J=7.7 Hz, 2 H), 1.63 (quint, J=7.7 
Hz, 2 H), 1.52 (quint, J=7.7 Hz, 2 H), 1.43 (s, 9 H), 1.27 (m, 2 H) ppm. HRMS (EI): calcd for 
C32H35N3O7 573.2475, found 573.2471. 
4.1.2.7. 6-(4-(2-Cyanophenoxy)-6-(2-((E)-1-(methoxycarbonyl)-2-methoxyvinyl)phenoxy)pyrimidin-
2-yl)hexanoic acid (Hapten AZb6, 3) 
Trifluoroacetic acid (522 µL) was added to a solution of tert-butyl ester 26 (43 mg, 0.075 mmol) 
in dry CH2Cl2 (522 µL) at 0 ºC. The mixture was stirred at rt for 20 minutes and then diluted with 
benzene. The mixture was concentrated under vacuum without heating and the residue obtained was 
purified by silica gel chromatography, using CHCl3/MeOH (95:5) as eluent, to give hapten AZb6 
(3, 37 mg, 95%) as a yellowish viscous oil. IR (NaCl): vmax=3213 (m), 3017 (m), 2233 (m), 1710 
(s), 1634 (m), 1588 (s), 1562 (s) cm
-1
. 
1
H NMR (300 MHz, CHCl3): =7.68 (dd, J=7.7, 1.6 Hz, 1 H, 
H-3 CN-Ph), 7.62 (td, J=7.7, 1.6 Hz, 1 H, H-5 CN-Ph), 7.51 (s, 1 H, H-2’), 7.39 (ddd, J=6.8, 7.9, 
2.3 Hz, 1 H, H-5 Ph), 7.33 (dd, J=6.8, 2.3 Hz, 1 H, H-3 Ph), 7.32 (td, J=7.7, 2.1 Hz, 1 H, H-4 
CN-Ph), 7.29 (td, J=6.8, 1.3 Hz, 1 H, H-4 Ph), 7.25 (br d, J=7.7 Hz, 1 H, H-6 CN-Ph), 7.21 (dd, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
28 
 
J=7.9, 1.3 Hz, 1 H, H-6 Ph), 6.08 (s, 1 H, H-5 pyrim), 3.75 (s, 3H, OCH3), 3.62 (s, 3 H, CO2CH3), 
2.66 (t, J=7.4 Hz, 2 H, H2-6), 2.28 (t, J=7.7 Hz, 2 H, H2-2), 1.64 (quint, J=7.4 Hz, 2 H, H2-5), 1.57 
(quint, J=7.7 Hz, 2 H, H2-3), 1.30 (m, 2 H, H2-4) ppm. 
13
C NMR (75 MHz, CHCl3): =179.06 
(COOH), 171.95 (C-4 pyrim), 171.36 (C-6 pyrim), 169.96 (C-2 pyrim), 167.61 (CO2Me), 160.92 
(C-2’), 154.38 (C-1 CN-Ph), 150.36 (C-1 Ph), 133.95 (C-5 CN-Ph), 133.38 (C-3 CN-Ph), 132.74 
(C-3 Ph), 129.15 (C-5 Ph), 126.05 (C-2 Ph), 125.70 (C-4 CN-Ph), 125.63 (C-4 Ph), 122.85 (C-6 
CN-Ph), 121.88 (C-6 Ph), 115.40 (CN), 107.11 (C-2 CN-Ph), 106.86 (C-1’), 88.76 (C-5 pyrim), 
62.01 (OCH3), 51.65 (CO2Me), 38.18 (C-6), 33.77 (C-2), 28.31 (C-4), 27.06 (C-5), 24.40 (C-3) 
ppm. MS (EI): m/z (%)=518 (M
+
+1, 24), 517 (M
+
, 89), 502 (37), 486 (98), 458 (52), 430 (41), 402 
(77), 398 (83), 386 (95), 359 (57), 326 (46), 267 (20), 223 (37), 191 (47), 176 (45), 145 (47), 119 
(63), 102 (65), 91 (100), 75 (68). HRMS (EI): calcd for C28H27N3O7 517.1849, found 517.1843. 
4.1.3. Synthesis of hapten AZc6 (4) 
4.1.3.1. 2-Hydroxy-5-iodobenzonitrile (27) 
Ag2SO4 (4.978 g, 15.967 mmol) was added in small portions to a stirred solution of 2-
cyanophenol (16, 1.902 g, 15.967 mmol) and I2 (4.457 g, 17.547 mmol) in dry CH2Cl2 (40.5 mL). 
The reaction mixture was stirred for 2 days at rt and filtered to removed the solids. The filtrate and 
washings (CHCl3) were successively washed with a 5% aqueous solution of sodium thiosulphate 
and brine, and dried over anhydrous Na2SO4. Evaporation of the solvent under reduced pressure 
gave almost pure the iodophenol 27 (3.258 g, 84%) as a white solid, which showed the same 
physical and spectroscopic data as those previously reported.
32
 
4.1.3.2. 2-(Benzyloxy)-5-iodobenzonitrile (28) 
Benzyl bromide (1.4 mL, 12.013 mmol) was added to a solution of anhydrous K2CO3 (1.66 g, 
12.013 mmol) and phenol 27 (2.676 g, 10.921 mmol) in dry DMF (20 mL). The mixture was stirred 
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for 4 h at rt, then poured into water and work up as usual with hexane. The residue was purified by 
silica-gel column, eluting with hexane/EtOAc (9:1), to afford benzyl ether 28 (2.77 g, 74%) as a 
white solid. Mp 75−77 ºC (from benzene). 1H NMR (300 MHz, CHCl3): =7.84 (d, J=2.2 Hz, 1 H), 
7.74 (dd, J=8.9, 2.2 Hz, 1 H), 7.38 (m, 5 H), 6.77 (d, J=8.9 Hz, 1 H), 5.20 (s, 2 H) ppm. HRMS 
(EI): calcd for C14H10INO 334.9807, found 334.9801. 
4.1.3.3. tert-Butyl 6-(4-(benzyloxy)-3-cyanophenyl)hex-5-ynoate (29) 
A solution of alkyne 11 (670 mg, 3.99 mmol) in anhydrous DMF (4.2 mL) and Et3N (4.2 mL) 
were consecutively added to a mixture of aryl iodide 28 (1.08 g, 3.2 mmol), CuI (80 mg, 0.42 
mmol) and (Ph3P)2PdCl2 (82 mg, 0.12 mmol) under nitrogen. The reaction mixture, originally 
yellowish that turned deep orange after a few minutes, was stirred at rt for 5½. h, poured into water 
and worked up with EtOAc. Chromatographic purification, using hexane/EtOAc (9.5:0.5) as eluent, 
afforded the aryl-alkyne 29 (1.18 g, 98 %) as a white solid. Mp 86−88 ºC (from benzene). 1H NMR 
(300 MHz, CHCl3): =7.60 (d,  J=2.1 Hz, 1 H), 7.49 (dd, J=8.8, 2.1 Hz, 1 H), 7.38 (m, 5 H), 6.91 
(d, J=8.8 Hz, 1 H), 5.21 (s, 2 H), 2.44 (t, J=7.1 Hz, 2 H), 2.38 (t, J=7.1 Hz, 2 H), 1.86 (quint, J=7.1 
Hz, 2 H), 1.45 (s, 9 H) ppm. HRMS (EI): calcd for C24H25NO3 375.1834, found 375.1828. 
4.1.3.4. tert-Butyl 6-(3-cyano-4-hydroxyphenyl)hexanoate (30) 
A mixture of aryl-alkyne 29 (315.6 mg, 0.841 mmol) and 10% Pd/C (33.4 mg) in EtOAc (4.3 
mL) was purged with nitrogen, hydrogen bubbled through the solution and the mixture kept under 
hydrogen at atmospheric pressure (balloon) during 7 h at rt. The reaction mixture was filtered 
through a short pad of Celite and the residue left after evaporation of the solvent was 
chromatographed on silica gel with hexane/Et2O (9:1) as eluent to give the phenol 30 (218.7 mg, 
90%) as colourless oil. 
1
H NMR (300 MHz, CHCl3): =7.27 (d, J=2.1 Hz, 1 H), 7.24 (dd, J=8.5, 2.1 
Hz, 1 H), 6.90 (d, J=8.5 Hz, 1 H), 6.76 (br s, 1 H), 2.53 (t, J=7.5 Hz, 2 H), 2.22 (t, J=7.4 Hz, 2 H), 
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1.60 (quint, J=7.4 Hz, 2 H), 1.57 (quint, J=7.5 Hz, 2 H), 1.44 (s, 9 H), 1.31 (m, 2 H) ppm. HRMS 
calcd for C17H23NO3 289.1678, found 289.1667. 
4.1.3.5. tert-Butyl 6-(3-cyano-4-(6-(2-((E)-1-(methoxycarbonyl)-2-methoxyvinyl)phenoxy) 
pyrimidin-4-yloxy)phenyl)hexanoate (32) 
A mixture of 6-chloropyrimidine 31 (122.4 mg, 0.382 mmol), Cs2CO3 (134.2 mg, 0.412 mmol) 
and phenol 30 (119.4 mg, 0.412 mmol) was dissolved in dry DMF (2.1 mL) at 85 ºC under nitrogen. 
The mixture was stirred at this temperature for 3 h, then cooled down to rt, poured into water and 
worked up as usual using EtOAc as the extraction solvent. Chromatographic purification, eluting 
with hexane/EtOAc (8:2), afforded the compound 32 (199 mg, 91%) as a yellowish oil. 
1
H NMR 
(300 MHz, CHCl3): =8.40 (s, 1 H), 7.49 (br s, 2 H), 7.45 (dd, J=8.6, 2.2 Hz, 1 H), 7.41 (ddd, 
J=7.7, 8.4, 2.3 Hz, 1 H), 7.35 (dd, J=7.7, 2.3 Hz, 1 H), 7.30 (td, J=7.7, 1.0 Hz, 1 H), 7.22 (dd, 
J=8.4, 1.0 Hz, 1 H), 7.18 (d, J=8.6 Hz, 1 H), 6.39 (s, 1 H), 3.74 (s, 3 H), 3.63 (s, 3 H), 2.65 (t, J=7.6 
Hz, 2 H), 2.22 (t, J=7.6 Hz, 2 H), 1.65 (quint, J=7.6 Hz, 2 H), 1.63 (quint, J=7.6 Hz, 2 H), 1.44 (s, 9 
H), 1.37 (m, 2 H) ppm. HRMS (EI), calcd for C32H35N3O7 573.2475, found 573.2485. 
4.1.3.6. 6-(3-Cyano-4-(6-(2-((E)-1-(methoxycarbonyl)-2-methoxyvinyl)phenoxy)pyrimidin-4-yloxy) 
phenyl)hexanoic acid (Hapten AZc6, 4) 
A solution of tert-butyl ester 32 (32 mg, 0.055 mmol) in dry CH2Cl2 (160 µL) was treated with 
CF3CO2H (160 µL) under nitrogen. The mixture was stirred at rt for 10 min and concentrated to 
dryness in vacuum; the residue was purified by chromatography, using CHCl3/MeOH (95:5) as 
eluent, to give hapten AZc6 (4, 25.9 mg, 90 %) as a viscous oil. IR (NaCl) vmax=3213 (m), 3019 
(m), 2234 (m), 1709 (s), 1629 (m), 1591 (s), 1570 (s) cm
-1
. 
1
H NMR (300 MHz, CHCl3): =8.41 (s, 
1 H, H-2 pyrim), 7.50 (s, 1 H, H-2’), 7.49 (d, J=2.3 Hz, 1 H, H-2 CN-Ph), 7.45 (dd, J=8.7, 2.3 Hz, 
1 H, H-6 CN-Ph), 7.41 (ddd, J=7.7, 8.2, 2.3 Hz, 1 H, H-5 Ph), 7.35 (dd, J=7.7, 2.3 Hz, 1 H, H-3 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
31 
 
Ph), 7.30 (td, J=7.7, 1.0 Hz, 1 H, H-4 Ph), 7.21 (dd, J=8.2, 1.0 Hz, 1 H, H-6 Ph), 7.18 (d, J=8.7 Hz, 
1 H, H-5 CN-Ph), 6.91 (br s, 1 H, COOH), 6.38 (s, 1 H, H-5 pyrim), 3.75 (s, 3 H, OCH3), 3.63 (s, 3 
H, CO2CH3), 2.66 (t, J=7.6 Hz, 2 H, H2-6), 2.36 (t, J=7.4 Hz, 2 H, H2-2), 1.68 (quint, J=7.4 Hz, 2 
H, H2-3), 1.67 (quint, J=7.6 Hz, 2 H, H2-5), 1.40 (m, 2 H, H2-4) ppm. 
13
C NMR (75 MHz, CHCl3): 
=178.81 (COOH), 171.71 (C-4 pyrim), 170.27 (C-6 pyrim), 167.52 (CO2Me), 160.84 (C-2’), 
157.89 (C-2 pyrim), 152.00 (C-4 CN-Ph), 150.10 (C-1 Ph), 140.81 (C-1 CN-Ph), 134.36 (C-6 
CN-Ph), 133.06 (C-2 CN-Ph), 132.74 (C-3 Ph), 129.18 (C-5 Ph), 125.98 (C-2 Ph), 125.92 (C-4 Ph), 
122.83 (C-5 CN-Ph), 122.01 (C-6 Ph), 115.34 (CN), 106.92 (C-3 CN-Ph), 106.85 (C-1’), 92.27 
(C-5 pyrim), 61.02 (OCH3), 51.65 (CO2Me), 34.63 (C-6), 33.66 (C-2), 30.51 (C-5), 28.33 (C-4), 
24.38 (C-3) ppm. MS (EI): m/z (%)=518 (M
+
+1, 6), 517 (M
+
, 20), 502 (42), 486 (15), 458 (100), 
440 (14), 414 (4), 343 (3), 145 (4), 75 (5). HRMS (EI), calcd for C28H27N3O7 517.1849, found 
517.1849. 
4.1.4. Synthesis of hapten AZo6 (5) 
4.1.4.1. tert-Butyl 6-((E)-2-(methoxycarbonyl)vinyloxy)hexanoate (34) 
PBu3 (72 µL, 0.291 mmol) was added to a solution of tert-butyl 6-hydroxyhexanoate
33
 (33; 
331.5 mg, 1.763 mmol) in anhydrous CH2Cl2 (19.3 mL) under nitrogen. The mixture was cooled to 
0 ºC and methyl propiolate (162 µL, 1.938 mmol) was then added drop wise via a syringe over 5 
minutes. The reaction mixture was allowed to reach rt and stirred for 30 min, during which time the 
initially colourless solution turned to yellow and finally to deep red. The reaction mixture was 
exposed to the air and stirred for 20 min in order to oxidize and facilitate the separation of the PBu3. 
The resulting black mixture was concentrated at reduced pressure and the residue was purified by 
chromatography, using hexane/EtOAc (8:2) as eluent, to give acrylate derivative 34 (445 mg, 93 %) 
as an oil. 
1
H NMR (300 MHz, CHCl3): =7.56 (d, J=12.6 Hz, 1 H), 5.16 (d, J=12.6 Hz, 1 H), 3.81 
(t, J=6.4 Hz, 2 H), 3.67 (s, 3 H), 2.20 (t, J=7.3 Hz, 2 H), 1.69 (quint, J=6.4 Hz, 2 H), 1.59 (quint, 
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J=7.3 Hz, 2 H), 1.41 (s, 9 H), 1.38 (m, 2 H) ppm. HRMS (ES): calcd for C14H24NaO5 [M+Na]
+
 
295.1521, found 295.1527. 
4.1.4.2. tert-Butyl 6-((Z)-2-(methoxycarbonyl)-2-iodovinyloxy)hexanoate (35) 
A solution of 34 (211 mg, 0.77 mmol) in CH2Cl (2 mL) was added to N-iodosuccinimide (235 
mg, 1.044 mmol) at rt under nitrogen. Then AcOH (80 µL, 1.386 mmol) was added and the mixture 
was stirred for 17 h. After this time, the red-wine solution formed was treated with Et3N (347 µL, 
2.49 mmol) and then stirred for 22 h, poured into water, and extracted with EtOAc. The combined 
organic extracts were washed with 10% aqueous solution of Na2S2O3 and brine, and dried over 
anhydrous Na2SO4. Chromatographic purification of the residue left after evaporation of the 
solvent, using hexane/EtOAc (from 9:1 to 8:2) as eluent, afforded, in order of elution, first the vinyl 
iodide 35 (172 mg, 74% based on recovered starting material) as a yellowish oil, followed by the 
starting compound 34 (54 mg). Spectral data for 35: 
1
H NMR (300 MHz, CHCl3): =7.71 (s, 1 H), 
4.16 (t, J=6.5 Hz, 2 H), 3.77 (s, 3 H), 2.23 (t, J=7.3 Hz, 2 H), 1.74 (quint, J=6.5 Hz, 2 H), 1.62 
(quint, J=7.3 Hz, 2 H), 1.43 (s, 9 H), 1.42 (m, 2 H) ppm. HRMS (ES): calcd for C14H23INaO5 
[M+Na]
+ 
421.0488, found 421.0496. 
4.1.4.3. tert-Butyl 6-((E)-2-(methoxycarbonyl)-2-(2-(benzyloxy)phenyl)vinyloxy)hexanoate (36) 
A mixture of vinyl iodide 35 (89 mg, 0.223 mmol), 2-(benzyloxy)phenylboronic acid (23, 79.7 
mg, 0.349 mmol), K3PO4 (148.38 mg, 0.699 mmol) and Pd(PPh3)4 (17 mg, 0.015 mmol) in a 
previously degassed mixture of dioxane (1.15 mL) and water (233 µL) was heated at 90 ºC with 
stirring under nitrogen for 7 h. The cooled mixture was poured into water and worked up with 
EtOAc in the usual manner to yield an oily residue. Purification by chromatography gave 
compound 36 (82.1 mg, 81%) as an oil. 
1
H NMR (300 MHz, CHCl3): =7.56 (s, 1 H), 7.32 (m, 5 
H), 7.23 (ddd, J=7.5, 8.1, 1.7 Hz, 1 H), 7.21 (dd, J=7.5, 1.7 Hz, 1 H), 6.97 (td, J=7.5, 1.0 Hz, 1 H), 
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6.94 (dd, J=8.1, 1.0 Hz, 1 H), 5.07 (s, 2 H), 3.97 (t, J=6.7 Hz, 2 H), 3.64 (s, 3 H), 2.16 (t, J=7.5 Hz, 
2 H), 1.63 (quint, J=6.7 Hz, 2 H), 1.54 (quint, J=7.5 Hz, 2 H), 1.43 (s, 9 H), 1.30 (m, 2 H) ppm. 
HRMS (ES): calcd for C27H34O6 454.2355, found 454.2377. 
4.1.4.4. tert-Butyl 6-((E)-2-(methoxycarbonyl)-2-(2-hydroxyphenyl)vinyloxy)hexanoate (37) 
Benzyl ether 36 (548 mg, 1.205 mmol) was dissolved in EtOAc (5.3 mL), 10% Pd/C (26 mg) 
was added to the solution and the mixture was hydrogenated at 1 atm of H2 pressure (balloon) for 1 
h. The catalyst was remove by filtration though a pad of Celite and rinsed with EtOAc. The solvent 
was removed under reduced pressure to give a clear yellow oil. Purification by column 
chromatography using hexane/EtOAc (from 9:1 to 7:3) gave the phenol 37 (368 mg, 84%) as an oil. 
1
H NMR (300 MHz, CHCl3): =7.67 (s, 1 H), 7.20 (ddd, J=7.4, 8.4, 1.7 Hz, 1 H), 7.14 (dd, J=7.4, 
1.7 Hz, 1 H), 6.95 (dd, J=8.4, 1.2 Hz, 1 H), 6.90 (td, J=7.4, 1.2 Hz, 1 H), 6.43 (br s, 1 H), 4.05 (t, 
J=6.5 Hz, 2 H), 3.75 (s, 3 H), 2.20 (t, J=7.4 Hz, 2 H), 1.68 (quint, J=6.5 Hz, 2 H), 1.58 (quint, J=7.4 
Hz, 2 H), 1.43 (s, 9 H), 1.34 (m, 2 H) ppm. HRMS (ES): calcd for C20H28O6 364.1886, found 
364.1877. 
4.1.4.5. tert-Butyl 6-((E)-2-(methoxycarbonyl)-2-(2-(6-chloropyrimidin-4-yloxy)phenyl)vinyloxy) 
hexanoate (38) 
A solution of phenol 37 (94 mg, 0.257 mmol) in anhydrous DMF (1 mL) was added to a solution 
of 4,6-dichoropyrimidine (38.5 mg, 0.257 mmol) and Cs2CO3 (84 mg, 0.257 mmol) in DMF (1 mL) 
at 0 ºC under nitrogen. The mixture was stirred at 0 ºC for 45 min, then poured into water and 
worked up as usual with EtOAc. Chromatographic purification of the residue obtained, using 
hexane/EtOAc (9:1) as eluent, gave the chloropyrimidine 38 (85.5 mg, 70%) as a yellowish oil. 
1
H 
NMR (300 MHz, CHCl3): =8.57 (d, J=0.6 Hz, 1 H), 7.50 (s, 1 H), 7.40 (ddd, J=7.2, 8.0, 3.0 Hz, 1 
H), 7.34 (dd, J=7.2, 3.0 Hz, 1 H), 7.31 (td, J=7.2, 1.2 Hz, 1 H), 7.16 (br d, J=8.0 Hz, 1 H), 6.75 (d, 
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J=0.6 Hz, 1 H), 3.92 (t, J=6.9 Hz, 2 H), 3.58 (s, 3 H), 2.19 (t, J=7.4 Hz, 2 H), 1.59 (quint, J=6.9 Hz, 
2 H), 1.56 (quint, J=7.4 Hz, 2 H), 1.43 (s, 9 H), 1.29 (m, 2 H) ppm. HRMS (ES): calcd for 
C24H29
35
ClN2O6 476.1714, found 476.1702. 
4.1.4.6. tert-Butyl 6-((E)-2-(methoxycarbonyl)-2-(2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)phenyl) 
vinyloxy)hexanoate (39) 
A solution of chloropyrimidine 38 (85.5 mg, 0.180 mmol), Cs2CO3 (58.4 mg, 0.18 mmol) and 2-
cyanophenol (31.3 mg, 0.18 mmol) in dry DMF (1.2 mL) was stirred at 85 ºC for 5 h under 
nitrogen. The mixture was cooled down to rt and worked up as usual with EtOAc. Purification by 
chromatography eluting with hexane/EtOAc (from 8:2 to 7:3) afforded the compound 39 (77.5 mg, 
80%) as an oil. 
1
H NMR (300 MHz, CHCl3): =8.38 (s, 1 H), 7.71 (dd, J=7.8, 1.6 Hz, 1 H), 7.66 
(td, J=7.8, 1.6 Hz, 1 H), 7.55 (s, 1 H), 7.40 (ddd, J=6.9, 8.0, 2.3 Hz, 1 H), 7.36 (td, J=7.8, 1.1 Hz, 1 
H), 7.34 (dd, J=6.9, 2.3 Hz, 1 H), 7.293 (br d, J=7.8 Hz, 1 H), 7.290 (td, J=6.9, 1.1 Hz, 1 H), 7.21 
(dd, J=8.0, 1.1 Hz, 1 H), 6.391 (s, 1 H), 3.95 (t, J=6.7 Hz, 2 H), 3.61 (s, 3 H), 2.18 (t, J=7.3 Hz, 2 
H), 1.61 (quint, J=6.7 Hz, 2 H), 1.56 (quint, J=7.3 Hz, 2 H), 1.42 (s, 9 H), 1.31 (m, 2 H) ppm. 
HRMS (ES): calcd for C31H33N3O7 559.2319, found 559.2313. 
4.1.4.7. 6-((E)-2-(Methoxycarbonyl)-2-(2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)phenyl)vinyloxy) 
hexanoic acid (Hapten AZo5, 5) 
Trifluoroacetic acid (0.5 mL) was added to a solution of tert-butyl ester 39 (40 mg, 0.072 mmol) 
in dry CH2Cl2 (0.5 mL) at 0 ºC. The mixture was stirred at rt for 20 min under nitrogen, the mixture 
was diluted with benzene and then concentrated under vacuum without heating. The residue 
obtained was purified by silica gel chromatography, using CHCl3/MeOH (90:1) as eluent, to give 
hapten AZo6 (5, 33.1 mg, 92%) as a yellowish viscous oil. IR (NaCl) vmax=3200 (m), 3071 (m), 
1708 (s), 1632 (s), 1591 (s), 1567 (s) cm
-1
. 
1
H NMR (300 MHz, CHCl3): =8.40 (s, 1 H, H-2 
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pyrim), 7.71 (dd, J=7.8, 1.6 Hz, 1 H, H-3 CN-Ph), 7.66 (td, J=7.8, 1.6 Hz, 1 H, H-5 CN-Ph), 7.56 
(s, 1 H, C-1’), 7.41 (ddd, J=7.7, 7.8, 2.7 Hz, 1 H, H-4 Ph), 7.36 (td, J=7.8, 1.0 Hz, 1 H, H-4 
CN-Ph), 7.34 (dd, J=7.7, 2.7 Hz, 1 H, H-6 Ph), 7.29 (br d, J=7.8 Hz, 1 H, H-6 CN-Ph), 7.30 (td, 
J=7.7, 0.8 Hz, 1 H, H-5 Ph), 7.21 (dd, J=7.8, 0.8 Hz, 1 H, H-3 Ph), 6.38 (s, 1 H, H-5 pyrim), 3.97 (t, 
J=7.2 Hz, 2 H, H2-6), 3.62 (s, 3 H, CO2CH3), 2.33 (t, J=7.2 Hz, 2 H, H2-2), 1.62 (quint, J=7.2 Hz, 4 
H, H2-5, H2-3), 1.36 (m, 2 H, H2-4) ppm. 
13
C NMR (75 MHz, CHCl3): =177.92 (COOH), 171.82 
(C-6 pyrim), 170.12 (C-4 pyrim), 167.62 (CO2Me), 159.86 (C-1’), 157.88 (C-2 pyrim), 154.08 (C-1 
CN-Ph), 150.21 (C-2, Ph), 134.19 (C-5 CN-Ph), 133.59 (C-3 CN-Ph), 132.78 (C-6 Ph), 129.18 (C-4 
Ph), 126.25 (C-1 Ph), 126.10 (C-4 CN-Ph), 125.93 (C-5 Ph), 123.03 (C-6 CN-Ph), 121.83 (C-3 Ph), 
115.18 (CN), 107.27 (C-2 CN-Ph), 106.54 (C-2’), 92.44 (C-5 pyrim), 74.95 (C-6), 51.60 (CO2Me), 
33.68 (C-2), 29.23 (C-5), 24.76 (C-4), 24.19 (C-3) ppm. MS (EI): m/z (%)=504 (M
+
+1, 5), 503 (M
+
, 
16), 444 (58), 388 (100), 329 (62), 301 (20), 176 (19), 172 (17), 145 (11), 102 (8), 69 (25), 55 (19). 
HRMS (ES): calcd for C27H25N3O7 503.1693, found 503.1718. 
4.2. Immunochemistry 
Procedure details and equipment for protein conjugation and immunoassay performance are 
given as supplementary data. 
4.2.1. Bioconjugate preparation 
Immunogens were prepared by coupling the haptens to BSA. In a first step, the carboxylate 
group of haptens was activated in DMF using either N-hydroxysuccinimide and N,N-
dicyclohexylcarbodiimide or N,N’-disuccinimidyl carbonate. Next, the coupling reaction was 
performed in buffer at a hapten-to-protein molar ratio of 44:1. On the other hand, assay coating 
conjugates were prepared using OVA as carrier. In this case, the activation of the carboxylate was 
accomplished using tributylamine and isobutyl chloroformate. The initial molar ratio in the 
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coupling reaction with this protein was 13:1. A brief description of the followed coupling 
procedures has been included as supplementary data. 
4.2.2. Polyclonal antibody production 
Animal manipulation was performed in compliance with the laws and guidelines of the Spanish 
Ministry of Science and Innovation (RD 1201/2005 and law 32/2007) and according to the 
European Directive 2003/65/EC concerning the protection of animals used for experimental and 
other scientific purposes. New Zealand white rabbits were immunized at three-week intervals with 
300 µg of BSA−hapten conjugate (see the supplementary data) following described standard 
protocols.
34
 Ten days after the fourth boost the animals were exsanguinated, the antisera were 
separated by centrifugation and precipitated twice with an ammonium sulphate saturated solution.  
4.2.3. Competitive ELISAs 
Ninety-six-well polystyrene ELISA plates were coated with 100 µL per well of OVA conjugate 
solution at 1.0 or 0.1 µg/mL in 50 mM carbonate−bicarbonate buffer, pH 9.6 by overnight 
incubation at rt. Plates were washed four times with a solution containing 150 mM NaCl and 0.05% 
(v/v) Tween 20. Bidimensional competitive assays were carried out in order to find the limiting 
concentrations of the immunoreagents. A serial dilution of azoxystrobin was prepared, in 
borosilicate glass tubes, with 10 mM phosphate buffer, pH 7.4 containing 140 mM NaCl, and the 
antisera were also serially diluted in the same buffer containing 0.05% (v/v) Tween 20. Each plate 
column received a complete standard curve of the analyte (50 µL per well) followed by a different 
dilution per column of a given antiserum (50 µL per well). The same distribution of the reagents 
was repeated for each plate with a different coating conjugate concentration. The immunological 
reaction took place during 1 h at rt, and plates were washed again as described. Next, 100 µL per 
well of a 1/10000 dilution of goat anti-rabbit immunoglobulin peroxidase conjugate in phosphate 
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buffer with Tween 20 was added, and plates were incubated 1 h at rt. After washing, retained 
peroxidase activity was determined by addition of 100 µL per well of freshly prepared 2 mg/mL o-
phenylenediamine and 0.012% (v/v) H2O2 solution in 25 mM citrate and 62 mM sodium phosphate 
buffer, pH 5.4. The enzymatic reaction was stopped after 10 min with 100 µL per well of 2.5 M 
H2SO4. 
The absorbance was immediately read at 492 nm with a reference wavelength at 650 nm. These 
simultaneous titration and competitive assays resulted in one inhibition curve per column 
corresponding to a certain combination of concentrations of the immobilized immunoreagent (OVA 
conjugate) and the immunoreagent in solution (antiserum). Sigmoidal curves were mathematically 
fitted to a four-parameter logistic equation using the SigmaPlot software package from SPSS Inc. 
(Chicago, IL). The antiserum titre was defined as the reciprocal of the dilution that results in a 
maximum absorbance value (Amax) around 1.0 reached at the zero dose of analyte. Antibody affinity 
or IC50 was estimated as the concentration of analyte at the inflection point of the fitted curve, 
typically corresponding to a 50% reduction of the Amax if the background signal approaches to zero. 
Cross-reactivity (CR) was calculated according to the formula: 
    CR = [IC50(AZE isomer)/IC50(AZZ isomer)] × 100 
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Supplementary Material  
This supporting information contains general details, experimental biochemical procedures, full 
spectral data and assignments for all intermediates of the synthesis of haptens 2 to 5, preparation 
and characterization data of compounds 40 and 41 and copies of the 
1
H NMR spectra of haptens 2 
to 5. Supplementary data associated with this article can be found in the online version, at doi: 
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Figure legends 
Fig. 1. Structure of azoxystrobin and regioisomeric haptenic derivatives. 
Fig. 2. Inhibition curves for azoxystrobin in homologous competitive assays using antibodies 
derived from AZa6 (circles), AZb6 (up triangles), AZc6 (squares) and AZo6 (down triangles). 
Fig. 3. Affinity of the different types of antisera towards two analogues of azoxystrobin. Black bars: 
compound 40; gray bars: compound 41. 
 
Scheme legends 
Scheme 1. Modular synthetic approach (a→ab→abc) for the preparation of azoxystrobin haptens. 
Scheme 2. Synthesis of hapten AZa6 (2). 
Scheme 3. Synthesis of hapten AZb6 (3). 
Scheme 4. Synthesis of hapten AZc6 (4). 
Scheme 5. Synthesis of hapten AZo6 (5). 
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